Human Papillomavirus genotype testing combined with cytology as a 'test of cure' post treatment: The importance of a persistent viral infection

Journal of Clinical Virology

Volumn 52, Issue 2, 2011, Pages 88-92

  Jones, Joanne ^a   Saleem, Azka ^a   Rai, Nima ^b   Shylasree, T S ^c   Ashman, Suzanne ^a   Gregory, Kate ^d   Powell, Ned ^a   Tristram, Amanda ^a   Fiander, Alison ^a   Hibbitts, Samantha ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

^c LLANDOUGH HOSPITAL   (United Kingdom)

^d Cervical Screening Wales   (United Kingdom)

Author keywords

Cervical screening; HPV genotyping; PapilloCheck ; Test of cure

Indexed keywords

ADULT; ARTICLE; ASSAY; CANCER GRADING; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOLOGY; FEMALE; GENOTYPE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PATIENT CARE; PERSISTENT VIRUS INFECTION; PREDICTION; PRIORITY JOURNAL; RECURRENT DISEASE; SAMPLE; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYTOLOGICAL TECHNIQUES; FEMALE; GENOTYPING TECHNIQUES; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RECURRENCE; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 80052721306     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.06.021     Document Type: Article

References (30)

1. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(1):12-19.
2. Munoz N. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 2000, 19(1-2):1-5.
3. Programmes NCS Cervical screening the facts 2011.
4. Ronco G., Giorgi-Rossi P., Carozzi F., Confortini M., Dalla Palma P., Del Mistro A., et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010, 11(3):249-257.
5. Cuzick J., Clavel C., Petry K.U., Meijer C.J., Hoyer H., Ratnam S., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006, 119(5):1095-1101.
6. Kitchener H.C., Gilham C., Sargent A., Bailey A., Albrow R., Roberts C., et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer 2011.
7. Stoler M.H., Wright T.C., Sharma A., Apple R., Gutekunst K., Wright T.L. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol 2011, 135(3):468-475.
8. Brismar S., Johansson B., Borjesson M., Arbyn M., Andersson S. Follow-up after treatment of cervical intraepithelial neoplasia by human papillomavirus genotyping. Am J Obstet Gynecol 2009, 201(1):e1-e8. 17.
9. Programmes NCS Cervical screening pocket guide 2009.
10. Programmes NCS HPV triage and test of cure flowchart 2011.
11. Paraskevaidis E., Arbyn M., Sotiriadis A., Diakomanolis E., Martin-Hirsch P., Koliopoulos G., et al. The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev 2004, 30(2):205-211.
12. Arbyn M., Sasieni P., Meijer C.J., Clavel C., Koliopoulos G., Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006, 24(Suppl. 3). S3/78-89.
13. Cuzick J. Role of HPV testing in clinical practice. Virus Res 2002, 89(2):263-269.
14. Heymans J., Benoy I.H., Poppe W., Depuydt C.E. Type-specific HPV geno-typing improves detection of recurrent high-grade cervical neoplasia after conisation. Int J Cancer 2010.
15. Kitchener H.C., Walker P.G., Nelson L., Hadwin R., Patnick J., Anthony G.B., et al. HPV testing as an adjunct to cytology in the follow up of women treated for cervical intraepithelial neoplasia. BJOG 2008, 115(8):1001-1007.
16. Wilson J.M.G., Jungner G. Principles and practice of screening for disease 1968, World Health Organization, Geneva.
17. Day NE. The epidemiological basis for evaluating different screening policies. IARC Sci Publ 1986;76:199-212.
18. Quinn M., Babb P., Jones J., Allen E. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 1999, 318:904-908.
19. Stoler M.H., Schiffman M. Atypical squamous cells of undetermined significane-low grade squamous Intraepithelial Triage Study, interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL triage study. JAMA 2001, 285:1500-1505.
20. Evaluation of cervial cytology. Evidence report technology assessment 5 1999, AHCPR Publication, Bethesda, MD.
21. Naucler P., Ryd W., Tornberg S., Strand A., Elfgren al e K. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009, 101(2):88-99.
22. Koliopoulos G., Arbyn M., Martin-Hirsch P., Kyrgiou M., Prendiville W., Paraskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta analysis of non-randomized studies. Gynecol Oncol 2007, 104:232-246.
23. Soutter W.P., de Barros Lopes A., Fletcher A., Monaghan J.M., Duncan I.D., Paraskevaidis E., et al. Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia. Lancet 1997, 349(9057):978-980.
24. Alonso I., Torne A., Puig-Tintore L.M., Esteve R., Quinto L., Campo E., et al. Pre- and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2-3. Gynecol Oncol 2006, 103(2):631-636.
25. Jones J., Powell N.G., Tristram A., Fiander A.N., Hibbitts S. Comparison of the PapilloCheck DNA micro-array Human Papillomavirus detection assay with Hybrid Capture II and PCR-enzyme immunoassay using the GP5/6+ primer set. J Clin Virol 2009, 45(2):100-104.
26. Szarewski A., Ambroisine L., Cadman L., Austin J., Ho L., Terry G., et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 2008, 17(11):3033-3042.
27. Duarte-Franco Mayrand.M.H., Rodrigues E., al e.I. Human papillomavirus DNA versus Papanicolaou tests for cervical cancer. N Eng J Med 2007, 357(16):1579-1588.
28. Arbyn M., Sasieni P., Meijer C.J., Clavel C., Koliopoulos G., Dillner J. Clinical applications of HPV Testing: a summary of meta-analysis. Vaccine 2006, 24(Suppl. 3):S78-S79.
29. Cuzick J., Clavel C., Petry al e.K.U. Overview of the European and Nort American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006, 119(5):1095-1101.
30. Kreimer A.R., Guido R.S., Solomon D., Schiffman M., Wacholder S., Jeronimo J., et al. Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease. Cancer Epidemiol Biomarkers Prev 2006, 15(5):908-914.